Impact of sacubitril/valsartan and gliflozins on cardiac resynchronization therapy response in ischemic and non-ischemic heart failure patients-Reference-Cited by-同舟云学术

Impact of sacubitril/valsartan and gliflozins on cardiac resynchronization therapy response in ischemic and non-ischemic heart failure patients

Published:2023-12 Issue: Volume:393 Page:131391
ISSN:0167-5273
Container-title:International Journal of Cardiology
language:en
Short-container-title:International Journal of Cardiology

Author:

Fonderico Celeste,Pergola Valerio,Faccenda Daniele,Salucci Alfonsomaria,Comparone Gianluigi,Marrese Aldo,Ammirati Giuseppe,Cocchiara Luigi,Varriale Alfonso,Esposito Giovanni,Rapacciuolo Antonio,Strisciuglio Teresa

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference29 articles.

1. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients;Desai;Eur. Heart J.,2015

2. Dapagliflozin in patients with heart failure and reduced ejection fraction;McMurray;N. Engl. J. Med.,2019

3. Empagliflozin in heart failure with a preserved ejection fraction;Anker;N. Engl. J. Med.,2021

4. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure;McDonagh;Eur. Heart J.,2021

5. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy;Glikson;Eur. Heart J.,2021

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Benefits of sacubitril/valsartan administration and physical training in cardiac rehabilitation: current trends and bibliometric analysis of the years 2015-2024;Balneo and PRM Research Journal;2024-06-21

2. Longitudinal comparison of dyssynchrony correction and ‘strain’ improvement by conduction system pacing: LEVEL-AT trial secondary findings;European Heart Journal - Cardiovascular Imaging;2024-05-20

3. Angiotensin Receptor/Neprilysin Inhibitor in Patients with an Implantable Cardioverter-Defibrillator: Systematic Review and Meta-Analysis;2024